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Summary
Background Adalimumab (ADA) (Humira, AbbVie Inc., U.S.A.) is approved by the
European Medicines Agency for children aged ≥ 4 years with severe plaque psoriasis.
Objectives To evaluate the long-term efficacy and safety of ADA in children with
severe plaque psoriasis.
Methods Results are presented from the 52-week long-term extension (LTE) of the
randomized, double-blind, double-dummy, phase III trial, in children with sev-
ere plaque psoriasis (results from prior periods have been published). Patients
aged ≥ 4 and < 18 years were randomized 1 : 1 : 1 to ADA 08 mg kg1 (40
mg maximum) or 04 mg kg1 (20 mg maximum) every other week or to
methotrexate (MTX) 01–04 mg kg1 (25 mg maximum) weekly. The 16-week
initial treatment (IT) period was followed by a 36-week withdrawal period and a
16-week retreatment period. Patients could enter the LTE at prespecified time
points to receive ADA 08 mg kg1 (blinded or open label) or ADA 04 mg kg1
(blinded), or to remain off treatment. Efficacy is reported for patient groups
according to doses received in the IT and LTE periods.
Results Of the 114 patients randomized in the IT period, 108 entered the LTE
(n = 36 in each group); 93 received ADA 08 mg kg1. Efficacy (≥ 75%
improvement from baseline in Psoriasis Area and Severity Index) was maintained
or improved from entry to the end of the LTE: MTX(IT)/ADA 08(LTE) 31–86%
of patients; ADA 04(IT)/04 or 08(LTE) 28–47%; ADA 08(IT)/08(LTE) 50–
72%. No serious infections occurred in the LTE.
Conclusions After 52 weeks of long-term ADA treatment in children aged 4–18 years
with severe plaque psoriasis, disease severity was reduced and maintained or further
improved, as demonstrated by efficacy outcomes. No new safety risks were identified.
What’s already known about this topic?
• The results from the first three periods of this phase III trial in children aged 4–18
years with severe plaque psoriasis suggest that adalimumab is a safe and efficacious
treatment option in this population.
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What does this study add?
• This is the first study to evaluate long-term treatment of adalimumab in children
with severe psoriasis, and the first to evaluate switching from methotrexate to adal-
imumab in this population.
Plaque psoriasis is a chronic inflammatory skin disease. Its over-
all prevalence for children 0–18 years of age is 02–14% in
Europe and approximately 1% in the U.S.A.1,2 The disease in
children and adults is associated with impaired quality of life3–5
and an increased risk of comorbidities, including obesity, meta-
bolic syndrome, cardiovascular risk, autoimmune diseases6–8
and psychosocial issues, especially depression.9–11
The limited number of approved systemic therapies and
randomized controlled trials evaluating treatment in children
has challenged the effective management of the disease. Con-
ventional treatment options include topical therapy for mild-
to-moderate disease,12 and for severe or refractory disease,
ultraviolet (UV)B phototherapy, narrowband UVB therapy if
accessible and systemic treatments, including methotrexate
(MTX), ciclosporin, acitretin (retinoids) and biologics.13–15
Approved biologic therapies for plaque psoriasis in children
include the tumour necrosis factor (TNF)-a inhibitors etaner-
cept16–19 and adalimumab (ADA),20 and the p40 inhibitor
ustekinumab.18,19 Etanercept is approved by the European
Medicines Agency (EMA) for children aged ≥ 6 years with
severe disease, and by the U.S. Food and Drug Administration
(FDA) for children aged ≥ 4 years; ADA is approved by the
EMA for children aged ≥ 4 years with severe chronic disease;
and ustekinumab is approved by the EMA and FDA for chil-
dren aged ≥ 12 years with moderate-to-severe disease.
Results of long-term treatment of children with moderate-to-
severe psoriasis have been published for open-label etaner-
cept,21,22 and for ustekinumab vs. placebo.23 Biologic treatment
of psoriasis in children is reported as less likely to result in
adverse events or in treatment discontinuation compared with
MTX.24
The current analysis reports results from the first random-
ized 52-week controlled trial, comparing the efficacy and
safety of a biologic treatment, ADA (Humira, AbbVie Inc.,
North Chicago, IL, U.S.A.), a recombinant fully human mono-
clonal antibody directed against TNF-a, with the active com-
parator MTX, in children with severe plaque psoriasis. Results
from the first three periods of this trial have been reported.25
Patients and methods
Participants
Patients were children aged ≥ 4 and < 18 years with a body
weight of ≥ 15 kg and severe plaque psoriasis for ≥ 6 months,
who had failed to respond to topical therapy. Severe psoriasis
was defined as meeting at least one of the following criteria: (i)
Physician’s Global Assessment (PGA) ≥ 4; (ii) body surface area
involved > 20%, or > 10% with very thick lesions; (iii) Psoriasis
Area and Severity Index (PASI) > 20, or PASI > 10 and at least
one of the following: active psoriatic arthritis unresponsive to
nonsteroidal anti-inflammatory drugs, Children’s Dermatology
Life Quality Index (CDLQI) >10, or clinically relevant facial,
genital or hand and/or foot involvement. Prior use of biologics
was not allowed, with the exception of etanercept (treatment up
to 4 weeks before the baseline visit was allowed). Allowed con-
comitant medications during the study included medicated
(noncorticosteroid) shampoos, bland (without beta- or alpha-
hydroxy acids) emollients, and inhaled corticosteroids for stable
medical conditions. Additional study inclusion criteria have
been published.25
Study design
This randomized, parallel-group, double-blind, phase III study
(ClinicalTrials.gov: NCT01251614) had four periods: primary
double-blind initial treatment (IT, 16 weeks), withdrawal (up to
36 weeks), retreatment (16 weeks) and long-term extension (LTE,
52 weeks) (Fig. 1). Results from the LTE are presented here.
Patients received blinded ADA 08 mg kg1 (up to 40 mg
total dose) or ADA 04 mg kg1 (up to 20 mg total dose) at
week 0 and then every other week starting at week 1, or 01–
04 mg kg1 MTX weekly (up to 25 mg per week total dose;
uptitrated for efficacy, as tolerated). Responders and nonre-
sponders were defined based on achievement of the primary
end points at week 16: ≥ 75% improvement from baseline in
PASI (PASI 75) and PGA of cleared (0) or minimal (1) disease
(PGA 0/1). The LTE was conducted in parallel to the other
study periods for up to 52 weeks and could be entered at
multiple time points (Fig. 1).
Evaluations
In the LTE, efficacy was summarized for three patient groups,
defined according to their initial randomized dose in the IT per-
iod and the dose received in the LTE: MTX (IT)/ADA 08 (LTE);
ADA 04 (IT)/04 or 08 (LTE); and ADA 08 (IT)/08 (LTE).
Given the study design, LTE dosing was complex; the majority of
patients received ADA 08 mg kg1 (open label or blinded) at the
start of or during the LTE, and as continued treatment from the
retreatment period or after switching from treatment withdrawal
or from ADA 04 mg kg1 during the LTE. For this reason, we
report results for all patients who entered the LTE, despite how,
when or whether they received ADA 08 mg kg1.
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Other LTE evaluations included the CDLQI and the Pediatric
Quality of Life Inventory. Absolute PASI values at score cate-
gories ≤ 5 and ≤ 3 were analysed post hoc across the IT per-
iod and the LTE. Safety was evaluated by treatment-emergent
adverse events. Efficacy and safety were also evaluated for the
subgroup of patients who failed MTX treatment in the IT per-
iod and were switched to ADA 08 mg kg1 in the LTE.
Statistical analysis
Efficacy was evaluated for all randomized patients (intention-
to-treat population) in the IT period (n = 114); the statistical
analysis and results have been reported previously.25 In the
LTE, the intention-to-treat population included all patients
who entered the LTE (n = 108). Missing data were imputed
using nonresponder imputation for dichotomous efficacy end
points and last observation carried forward for continuous end
points. The safety population consisted of all who received at
least one dose of study medication in the trial. As the majority
(926%, 100 of 108) of patients received ADA during the
LTE, no statistical comparisons among efficacy groups were
performed in the LTE.
Results
Of the 114 initially randomized patients (MTX, n = 37; ADA
04 mg kg1, n = 39; ADA 08 mg kg1, n = 38), 108
entered the LTE (n = 36 in each efficacy group) (Fig. 2).
Patients who entered the LTE according to prespecified entry
criteria included eight who escaped the IT period early (n = 6
at week 4 and n = 2 at week 8), 51 who were nonresponders
at the end of the IT period, 15 who completed the IT period
and did not lose disease control at the end of the treatment
withdrawal period, and 34 who completed the IT period, lost
disease control in the withdrawal period and completed the
retreatment period.
The majority of the 108 patients who entered the LTE
received ADA 08 mg kg1 in the LTE (Fig. 2): 100 received
any ADA (04 or 08 mg kg1) and 93 received any ADA 08
mg kg1 dose. Of these, 83 of 93 received open-label or
blinded ADA 08 mg kg1 from the start of the LTE, and 88
of 93 received ADA 08 mg kg1 from their first dose in the
LTE. Four of 93 patients started the LTE off drug, lost disease
control and were switched to blinded ADA 08 mg kg1 in
the LTE, and an additional six of 93 switched from double-
blind ADA 04 mg kg1 to open-label ADA 08 mg kg1 in
the LTE (Fig. 2).
Eight of the 15 patients who did not lose disease control in
the withdrawal period and who continued off treatment in
the LTE remained off drug in the LTE, and seven of 15 lost
disease control in the LTE and were re-treated with the same
blinded dose they received in the IT period (or with ADA 08
mg kg1 for those initially randomized to MTX in the IT per-
iod); this included three who were re-treated in the LTE with
ADA 04 mg kg1 and four who were re-treated with ADA
08 mg kg1.
Fig 1. Study design. aAdalimumab (ADA) 08 mg kg1 up to 40 mg at week 0; every other week (eow) from week 1. bADA 04 mg kg1 up to
20 mg at week 0; eow from week 1. cMethotrexate (MTX) 01–04 mg kg1 every week (ew) up to 25 mg per week. dResponders or
nonresponders were patients who achieved or did not achieve ≥ 75% improvement in Psoriasis Area and Severity Index and a Physician’s Global
Assessment (PGA) score of 0 or 1 at the end of the initial treatment (IT) period. ePatients who lost disease control in the long-term extension
(LTE) could receive ADA until the end of the LTE at the initial randomized dose, or ADA 08 mg kg1 if the initial randomized drug was MTX.
Patients entering the withdrawal period initially randomized to MTX received blinded ADA 08 mg kg1 in the retreatment period and the LTE.
Patients initially randomized to ADA 04 mg kg1 or 08 mg kg1 received blinded ADA in the retreatment period and the LTE based on their
initial randomized dose. All patients had a dose-increase option to open-label ADA 08 mg kg1 in the LTE.
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In total 18 of 108 patients (167%) discontinued the LTE;
the primary reason was lack of efficacy (n = 10). The median
exposure to any ADA dose was 364 days (range 42–380) dur-
ing the LTE (n = 100), and 392 days (range 21–611) during
the entire study (n = 111). The baseline demographics and
disease characteristics were balanced among the IT-period dose
groups.25 The most commonly reported concomitant topical
medications were salicylic acid (6%) and emollients and pro-
tectives (53%).
At baseline, the mean  SD patient body weight (513 
203 kg) and body mass index (BMI) (211  49 kg m2)
were balanced across baseline treatment groups (MTX, ADA
04 mg, ADA 08 mg). The numbers of patients in each BMI
category (based on age- and sex-specific World Health Orga-
nization BMI charts) were 68 of 114 (596%) normal weight,
17 (149%) overweight and 24 (211%) obese; the percent-
ages of patients within each category were also balanced
across baseline treatment groups.25
There were no trends regarding the percentages of patients
achieving PASI 75 across the BMI categories of normal weight,
overweight and obese: MTX(IT)/ADA 08(LTE), 90%, 100%,
63% (n = 21, 6, 8, respectively); ADA 04(IT)/ADA 04 or
08(LTE), 48%, 50%, 50% (n = 23, 4, 8, respectively); ADA
08(IT)/ADA 08(LTE), 75%, 57%, 83% (n = 20, 7, 6, respec-
tively). The small numbers of patients in each of the over-
weight and obese categories limit any interpretation of these
results.
Efficacy
Treatment response, measured by achievement of PASI 75,
PASI 90 and PASI 100, improved for all efficacy groups from
the start of the LTE across 52 weeks of treatment (Fig. 3). At
LTE week 52, PASI 75, 90 and 100 response rates for each
efficacy group were higher than the corresponding rates at
week 16 of the IT period. Response measured by achievement
of PGA 0/1 also improved for all efficacy groups from the
start of the LTE across 52 weeks of treatment, and rates at LTE
week 52 for the MTX(IT)/ADA 08(LTE) and ADA 04(IT)/
04 or 08(LTE) groups were higher than the corresponding
rates at week 16 of the IT period (Fig. 4). Patients in the
MTX(IT)/ADA 08(LTE) group had a higher response rate at
LTE week 52 than those in the other two efficacy groups for
all efficacy measures (Figs. 3 and 4).
Treatment response measured by absolute PASI ≤ 3 and ≤ 5
also improved for all three efficacy groups from the start of
the LTE across 52 weeks of treatment, and the rates at week
52 for each efficacy group were higher than the correspond-
ing rates at week 16 of the IT period, except for PASI ≤ 5 for
the ADA 04(IT)/04 or 08(LTE) groups (Fig. 5).
Patients unresponsive to MTX in the IT period who at the
end of that period were transitioned directly to the LTE to
receive open-label ADA 08 mg kg1 experienced improved
treatment response as measured by PASI 75 and PASI 90 as
early as 4 weeks after switching to ADA, and generally
Fig 2. Patient disposition. Efficacy in the long-term extension (LTE) was analysed for three groups, defined by the initial randomized dose (initial
treatment, IT) and the dose received in the LTE. aPatients entering the LTE from the withdrawal period with no loss of disease control who
subsequently lost response in the LTE could be re-treated with blinded adalimumab (ADA) [at the same initial randomized dose or ADA 08 mg
kg1 if initially randomized to methotrexate (MTX)]. Of the 15 patients who did not lose disease control in the withdrawal period and continued
off treatment in the LTE, eight remained off drug in the LTE [three MTX(IT)/ADA 08(LTE), three ADA 04(IT)/04 or 08(LTE), two ADA 08
(IT)/08(LTE)] and seven lost disease control in the LTE and were re-treated with the same dose they received in the IT period or with ADA 08
mg kg1 if initially randomized to MTX [two MTX(IT) and two ADA 08(IT) were re-treated with ADA 08 mg kg1 in the LTE, and three ADA
04(IT) were re-treated with ADA 04 mg kg1 in the LTE]. Of the patients initially treated with ADA 04 mg kg1 who entered the LTE, six
switched to ADA 08 mg kg1 open label during the LTE. W, week.
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(a)
(b)
(c)
Fig 3. Proportions of patients achieving (a) ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75), (b) PASI 90 and (c) PASI 100 response
(intention-to-treat population; nonresponder imputation). a0% for PASI 75, 90 and 100 at initial treatment (IT) week 1 for all dose groups and at IT week
4 for methotrexate (MTX); 0% for PASI 100 at IT week 4 for adalimumab (ADA) 04 mg kg1, and at IT weeks 8 and 11 for MTX. Statistically significant
at ***P= 0001, **P= 001, *P= 005 levels for MTX vs. ADA 04 mg kg1 or MTX vs. ADA 08 mg kg1 dosage in the IT period. Efficacy groups in the
long-term extension (LTE) are defined based on the initial randomization assignment in the IT period and on the dose received in the LTE.
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maintained the respective level of response through the rest of
the LTE (Fig. 6a). The PASI 100 response rate for these
patients also improved starting at LTE week 4, and continued
to improve to the end of the period (Fig. 6a). The PGA 0/1
response rate improved from weeks 1 to 11 and then slightly
decreased by the end of the period (Fig. 6b).
Improvements in quality-of-life scores during the LTE were
highest for patients initially randomized to ADA 08 mg kg1.
For all efficacy groups, quality-of-life scores at the end of the
IT period, as measured by CDLQI and Pediatric Quality of Life
Inventory, improved across the 52 weeks of the LTE (Table 1).
Safety
During the LTE, there were 4074 adverse events per 100
patient-years (PYs) (Table 2). The most frequently reported
events (≥ 20% of patients) were nasopharyngitis and head-
ache. Injection-site reactions occurred in 37% of patients
(four of 108). There were no malignancies.
Five serious adverse events occurred during the LTE (five of
108, 46% overall) (Table 2). Eight patients (eight of 108,
74%) reported severe adverse events, one of whom discontin-
ued the study drug (Table 2). One patient had a moderate
event of herpes zoster in the LTE that the investigator consid-
ered to be possibly related to ADA. Overall, a higher rate of
events related to allergic reactions (urticaria, pruritus, bron-
chospasm and asthma) was seen for patients initially random-
ized to MTX (182 events per 100 PYs) than for patients
initially randomized to ADA (45 events per 100 PYs); there
were no serious events related to allergic reaction.
For patients who failed MTX at week 16 of the IT period (n
= 19), the rate of adverse events during the LTE was 3815
per 100 PYs for any event, 57 per 100 PYs for serious events,
1422 per 100 PYs for infections and 569 per 100 PYs for
events at least possibly related to ADA.
There were no serious infections. Infections included upper
respiratory tract infection (n = 5), nasopharyngitis (n = 4),
rhinitis (n = 2), influenza (n = 2), pharyngitis (n = 2), bron-
chitis (n = 2), oral herpes (n = 1), gastroenteritis (n = 1), oti-
tis media (n = 1) and urinary tract infection (n = 1).
Discussion
Treatment of children with severe chronic psoriasis remains a
challenge. Standardized treatment guidelines are lacking and the
evidence for the efficacy and safety of systemic treatments in
paediatric psoriasis is limited. The treatment approach is based
on systemic treatments for adults, even though most of these
drugs are not approved for paediatric use.26 While MTX was
first investigated in this clinical trial, only retrospective case ser-
ies are available for drugs such as ciclosporin and acitretin.26–28
The chronicity of psoriasis and its negative effect on patient
quality of life can necessitate long-term treatment, thus the effi-
cacy and safety of long-term systemic therapy are important in
this population. However, they have been evaluated in only a
few clinical trials, which show the strongest evidence for
Fig 4. Achievement of Physician’s Global Assessment (PGA) 0 or 1 response (intention-to-treat population; nonresponder imputation). Statistically
significant at ***P= 0001, **P= 001, *P= 005 levels for methotrexate (MTX) vs. adalimumab (ADA) 04 mg kg1 or MTX vs. ADA 08 mg
kg1 dosage in the initial treatment (IT) period. Efficacy groups in the long-term extension (LTE) are defined based on the initial randomization
assignment in the IT period, and on the dose received in the LTE.
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biologics.21–23,29 Methotrexate is approved for adult plaque
psoriasis only, but up to now has been the first-line systemic
agent recommended for paediatric psoriasis.14
Biologics have significantly changed psoriasis treatment over
the decades and have greatly improved patients’ health-related
quality of life and patient-relevant outcomes.30–33 ADA has
been used to treat adults with moderate-to-severe plaque psori-
asis for over a decade, and has shown superior efficacy to sys-
temic treatments, such as MTX. Its accumulating safety data
resulted in a first-line label for adults and children.34,35 By
blocking TNF-a, ADA inhibits inflammation in psoriatic lesions
by decreasing the level of proinflammatory cytokines. Other
(a)
(b)
Fig 5. Achievement of absolute Psoriasis Area and Severity Index (PASI) ≤ 5 and ≤ 3 (intention-to-treat population; nonresponder imputation).
(a) Absolute PASI ≤ 5. (b) Absolute PASI ≤ 3. Statistically significant at **P= 001, *P= 005 levels for methotrexate (MTX) vs. adalimumab
(ADA) 04 mg kg1 or MTX vs. ADA 08 mg kg1 dosage in the initial treatment (IT) period. Efficacy groups in the long-term extension (LTE)
are defined based on the initial randomization assignment in the IT period, and on the dose received in the LTE.
© 2019 The Authors British Journal of Dermatology
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biologics approved for the treatment of children with plaque
psoriasis are etanercept (age ≥ 6 years with severe disease) and
ustekinumab (age ≥ 12 years with moderate-to-severe disease).
In this active-comparator-controlled study, response at the
end of the initial 16 weeks to ADA 08 mg kg1 was main-
tained through the 52-week LTE period of this trial. These
results in children with severe psoriasis are consistent with
results from ADA clinical trials in adults with moderate-to-
severe psoriasis. In an analysis of 250 adults, PASI 75, 90
and 100 rates after 160 weeks of ADA treatment were 76%,
50% and 31%, respectively,36 compared with 685%, 481%
and 296% of children overall in the current study. In an
interim analysis from a 10-year observational registry of ADA
treatment in adults (n = 6059), PGA 0/1 was achieved
(a)
(b)
Fig 6. Efficacy for methotrexate (MTX) nonresponders at week 16 who switched to adalimumab (ADA) in the long-term extension (LTE)
(intention-to-treat population; nonresponder imputation). (a) ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75), PASI 90 and
PASI 100. (b) Physician’s Global Assessment (PGA) score of 0 or 1. There were 19 patients who failed MTX treatment in the initial treatment (IT)
period, entered the long-term extension (LTE) at the end of the IT period (week 16) and received open-label ADA 08 mg kg1 during the LTE.
© 2019 The Authors British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019) 181, pp1177–1189
1184 Efficacy and safety of adalimumab in paediatric psoriasis, Thaci et al.
between 3 and 5 years of treatment by > 60% of adults,
compared with 602% of children overall in the current
study.37
Similar results have also been reported in trials of other bio-
logic therapies approved for moderate-to-severe psoriasis in
children. A 5-year open-label extension study of etanercept
confirmed its efficacy (70%, 40% and 50% achievement rates
for PASI 75, PASI 90 and PGA 0/1) following long-term treat-
ment, with no new safety concerns.21 In a 52-week random-
ized, placebo-controlled trial, response rates for the standard
ustekinumab dose were generally maintained from week 12
through 1 year (PASI 75, 806%; PASI 90, 611%; PGA 0/1,
694%), with no unexpected adverse events.23
Using absolute PASI as a treatment goal may provide more
objective clinical information about the efficacy of a treatment,
as it reflects the improvement of a patient’s disease severity
independently from the baseline value. The achievement rate
of each absolute PASI cut-off (≤ 5 and ≤ 3) in this study was
numerically higher at week 52 of the LTE than at LTE entry,
for each LTE efficacy group, and thus may represent a treat-
ment goal achievement of minor disease symptoms.
Patients with psoriasis onset at a young age are likely to
have more depression, sleep problems and social discrimina-
tion, and a higher lifetime Dermatology Life Quality
Index,38,39 even more so with severe psoriasis. Physical, psy-
chological and social impairments might have a significant
impact on the development of these patients and might result
in an inability to achieve ‘full-life potential’ (also termed
cumulative life course impairment) early in their lives.40
Therefore, there is still an unmet medical need to provide
long-term effective and safe psoriasis therapy to patients at a
young age in order to control disease chronicity and limit its
consequences on patient quality of life. The results from this
first comparative study showed that at the initial 16 weeks,
patients’ quality of life improved in relation to their clinical
response, and was maintained throughout the 52-week period.
Patients initially randomized to ADA 08 mg kg1 showed the
greatest mean improvement in quality-of-life scores during
the LTE compared with the other groups.
For the subgroup who did not respond to MTX treatment in
the IT period and continued directly to open-label treatment
with ADA 08 mg kg1 in the LTE, the majority achieved PASI
75, PASI 90 and PGA 0/1 (80%) response throughout the LTE,
starting as early as week 4. This improvement after switching is
consistent with results of other trials in adults with moderate-
to-severe psoriasis. In an open-label trial, 61% of patients (n =
41) who had failed prior treatment with MTX achieved PGA 0/
1 after 16 weeks of ADA.41 In an open-label randomized con-
trolled trial, patients who switched from initial treatment with
MTX (n = 215) to infliximab (n = 63) had a higher response
rate at week 26 than patients who did not switch (73% vs.
307% achieved PASI 75, and 75% vs. 28% achieved PGA 0/
1).42 In a real-world practice study, patients (n = 267)
improved their skin response following a switch to biologics
after treatment with conventional systemic agents. In that study
the mean time to first follow-up after switching was 6 weeks,
and the mean  SD PASI scores before and after switching were
136  88 and 57  58, respectively.43
In the current study, following ADA 08 mg kg1 treatment
in the LTE, the MTX responders in the IT period had a gener-
ally greater treatment response rate across efficacy outcomes
than MTX nonresponders in the IT period. Possible reasons
include lack of a washout period for nonresponders, or more
patients who escaped early in the IT period entering the LTE.
In general, the response rates for both groups were greater
than the rates in the LTE for patients who received ADA in the
IT period and in the LTE.
The ADA safety profile across all efficacy groups during the
52-week LTE was similar to the 16-week IT period profile,25
including low numbers of serious adverse events, severe
adverse events, injection-site reactions and allergic reactions,
and was therefore consistent with the known safety profile of
Table 1 Quality-of-life outcomes (intention-to-treat population, last observation carried forward)
Quality-of-life measure Week/period
Efficacy groups (by treatment received in the IT and LTE periods)
MTX(IT)/ADA 08(LTE) ADA 04(IT)/04 or 08(LTE) ADA 08(IT)/08(LTE)
CDLQIa n = 36, week 16/IT n = 37, week 16/IT n = 38, week 16/IT
n = 35, week 52/LTE n = 34, week 52/LTE n = 36, week 52/LTE
% change from BL, mean  SD 16/IT 400  584 458  552 572  483
52/LTE 700  535 550  467 672  432
% change from BL, median (IQR) 16/IT 648 (824, 138) 625 (900, 0) 736 (944, 409)
52/LTE 933 (1000, 600) 742 (909, 273) 869 (1000, 500)
PedsQLb n = 37, week 16/IT n = 38, week 16/IT n = 38, week 16/IT
n = 36, week 52/LTE n = 36, week 52/LTE n = 36, week 52/LTE
% change from BL, mean  SD 16/IT 30  147 185  282 186  302
52/LTE 143  288 610  2195 243  327
% change from BL, median (IQR) 16/IT 45 (48, 100) 104 (32, 229) 105 (0, 293)
52/LTE 96 (30, 181) 170 (40, 302) 130 (37, 303)
ADA, adalimumab; BL, baseline; CDLQI, Children’s Dermatology Life Quality Index; IT, initial treatment; LTE, long-term extension; MTX,
methotrexate; PedsQL, Pediatric Quality of Life Inventory. aNegative change indicates improvement. bPositive change indicates improvement.
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ADA in adults with psoriasis. No serious infections were
observed during the LTE. Rates for adverse events leading to
discontinuation, allergic reactions or injection-site reactions
were low. The most common adverse events were
nasopharyngitis and upper respiratory tract infections.
Similar safety results were seen in the long-term etanercept
(n = 182) and ustekinumab (n = 110) trials in children with
moderate-to-severe psoriasis,21,23 including the rate of the
more common adverse events of nasopharyngitis (259%
ADA, 260% etanercept) and upper respiratory tract infection
(120% ADA, 127% ustekinumab). Low rates were observed
(ADA, etanercept and ustekinumab, respectively) for serious
adverse events (46%, 38% and 45%), serious infections
(0%, 11% and 18%), tuberculosis (19%, not reported and
0%) and injection-site reactions (37%, 88% and 09%). No
malignancies or opportunistic infections were observed in any
of these long-term trials.
The long-term safety profile of ADA from this study is also
supported by the safety profiles from other trials of long-term
ADA treatment of adults and children with psoriasis and other
indications (rheumatoid arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis, psoriatic arthritis and Crohn disease).
The adverse events observed in these trials and analyses are
similar to those experienced by the current paediatric
Table 2 Treatment-emergent adverse events in the long-term extension (LTE)
Efficacy group (by treatment received in the IT and LTE periods)
MTX(IT)/ADA
08(LTE), n =36
ADA 04(IT)/04 or
08(LTE), n =36
ADA 08(IT)/
08(LTE), n =36 Total, n =108a
3110 PYs 2481 PYs 3073 PYs 8664 PYs
AEs, n (per 100 PYs)
Any AE 144 (4630) 90 (3628) 199 (3872) 353 (4074)
Serious AE 1 (32) 1 (40) 3 (98) 5 (58)
Severe AE 4 (129) 3 (121) 2 (65) 9 (104)
AE leading to study discontinuation 0 1 (40) 1 (33) 2 (36)
Infections 41 (1318) 37 (1491) 47 (1529) 125 (1443)
Serious infections 0 0 0 0
Tuberculosis 0 1 (40) 1 (33) 2 (23)
Worsening/new onset of psoriasis 2 (64) 4 (161) 2 (65) 8 (92)
Allergic reactionb 4 (129) 0 0 4 (45)
Injection-site reaction 1 (32) 1 (40) 5 (163) 7 (81)
AE leading to deathc 0 0 1 (33) 1 (12)
AEs, n (%)
Any AE 28 (78) 24 (67) 33 (92) 85 (787)
Serious AEd 1 (3) 1 (3) 3 (8) 5 (46)
Severe AEe 3 (8) 3 (8) 2 (6) 8 (74)
AE leading to study discontinuation 0 1 (3) 1 (3) 2 (19)
Infections 22 (61) 15 (42) 25 (69) 62 (574)
Serious infections 0 0 0 0
Tuberculosis 0 1 (3) 1 (3) 2 (19)
Worsening/new onset of psoriasis 2 (6) 4 (11) 2 (6) 8 (74)
Allergic reactionb 3 (8) 0 0 3 (28)
Injection-site reaction 1 (3) 1 (3) 2 (6) 4 (37)
AE leading to deathc 0 0 1 (3) 1 (09)
Most common AEs (≥ 10% of patients overall)
Nasopharyngitis 7 (19) 7 (19) 14 (39) 28 (259)
Headache 5 (14) 6 (17) 12 (33) 23 (213)
Upper respiratory tract infection 7 (19) 2 (6) 4 (11) 13 (120)
Nausea 3 (8) 3 (8) 5 (14) 11 (102)
ADA, adalimumab; AE, adverse event; IT, initial treatment; MTX, methotrexate; PY, patient-years. aIncluded patients who received at least
one dose of study drug during the trial. bIncluded angio-oedema, anaphylaxis, lupus-like reactions and systemic lupus erythematosus. cAcci-
dental fall leading to death. dSerious events included death from accidental fall 11 days post-treatment [ADA 08(IT)/08(LTE), n = 1], chest
pain [MTX(IT)/ADA 08(LTE), n = 1], tendon injury [ADA 04(IT)/04 or 08(LTE), n = 1], eye naevus [ADA 08(IT)/08(LTE, n = 1] and
maculopapular rash [ADA 08(IT)/08(LTE), n = 1], all considered by the investigator as not or probably not related to the study drug,
except eye naevus (possibly related). (e) Severe events included fall, chest pain and tendon injury (see ‘d’ above), as well as events in one
patient each of abdominal pain, bronchitis and extremity pain [MTX(IT)/ADA 08(LTE)], upper respiratory tract infection [ADA 04(IT)/04
or 08(LTE), n = 1; ADA 08(IT)/08(LTE), n = 1] and psoriasis worsening [ADA 04(IT)/ADA 04 or 08(LTE), n = 1] resulting in ADA dis-
continuation. There were no infectious AEs of oral candidiasis or active tuberculosis, and no malignancies.
© 2019 The Authors British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019) 181, pp1177–1189
1186 Efficacy and safety of adalimumab in paediatric psoriasis, Thaci et al.
population.35–37,44,45 The rates of events per 100 PYs were
similar across these trials and analyses. The adverse event rate
for IT MTX responders who received ADA 08 mg kg1 in the
LTE was similar to the rates for patients receiving ADA in the
other study periods.
A limitation of this study is the relatively small number of
patients in each efficacy group during the LTE, which makes
definitive conclusions difficult.
In conclusion, this study demonstrated that the efficacy of
ADA 08 mg kg1 dosed every other week was maintained
through 52 weeks of treatment for this population of children
with severe plaque psoriasis. For patients unresponsive to
MTX after 16 weeks, treatment response improved after
switching to open-label ADA 08 mg kg1 every other week,
and was generally maintained during 52 weeks of treatment
in the extension period. No new safety risks were identified.
These findings support the use of ADA as a long-term treat-
ment option for children with severe plaque psoriasis.
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